相关实验视频

Updated: May 11, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

从具有耐药GIST突变的Retama单精子中获得的黄类的分子对接和动态分析

Kaoutar El Khattabi¹, Jihane Akachar¹, Sanaa Lemriss²

¹Medical Biotechnology Laboratory, Rabat Medical and Pharmacy School, Mohammed V University in Rabat, Rabat, Morocco.

|February 7, 2025

概括

作为一种天然的黄类化合物,卢特在克服胃肠道 stromal 瘤 (GISTs) 中的氨酸激酶抑制剂耐药性方面表现有前途. 这种化合物有效地向关键突变,为GIST治疗提供了潜在的新疗法策略.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
计算化学计算化学

背景情况:

胃肠道 stromal 瘤 (GIST) 是消化道中最常见的介质细胞瘤.
在c-Kit和PDGFRα中激活突变是GIST发展的主要驱动因素.
对氨酸激酶抑制剂 (TKIs) 的耐药性是一个重大的临床挑战,需要新的治疗方法.

研究的目的:

调查从Retama单种精子中获得的黄胺 (Luteolin) 的潜力,作为治疗GIST的治疗剂.
评估丁素与c-Kit和PDGFRα的结合 afinities 和相互作用,包括耐药突变.
通过计算方法来评估Luteolin的药物相似性和稳定性.

主要方法:

用分子对接模拟来评估素与c-Kit和PDGFRα的结合亲和力.
吸收,分布,新陈代谢,分泌和毒性 (ADMET) 属性得到预测.
为了评估复杂的稳定性,对100 ns进行了分子动态模拟.
分析了与特定耐药突变 (c-Kit D816H,PDGFRα T674I) 的结合亲缘关系.

主要成果:

氨酸对PDGFRα (-8.1 kcal/mol) 和c-KIT (-9.6 kcal/mol) 具有很高的结合亲和力,与已批准的TKIs相似.
该化合物表现出有利的ADMET特性,并与目标残留物形成显著的和疏水性相互作用.
分子动力学模拟证实了稳定的luteolin-target复合体.
素显示出强大的结合性和增强的稳定性对抗抗性GIST突变 (c-Kit D816H,PDGFRα T674I).

结论:

氨酸具有作为c-Kit和PDGFRα的双重抑制剂的显著潜力.
它能够向耐药突变的能力表明,它可能是用于治疗GIST的传统TKI的有希望的替代品.
像丁醇这样的天然化合物需要进一步研究新的癌症疗法.

关键词:

胃肠道 stromal 瘤在胃肠道雷塔马单种子 (Retama) 是一个单种子.黄类化合物黄类化合物分子对接的分子对接.分子动力学模拟,分子动力学模拟

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...